Dr. Stephanie Estima

Most Oral Peptides Don't Work

The video asserts that oral administration of most peptide therapeutics fails, highlighting a fundamental limitation in the market. It explains that peptide size, exemplified by insulin's 52‑amino‑acid chain, leads to enzymatic degradation in the gastrointestinal tract, making injection necessary; only peptides small enough can be absorbed. The speaker notes, "If they could do an insulin pill, every diabetic would be taking it," underscoring the demand for oral options, and advises consumers to select only those peptides with proven oral bioavailability. This reality constrains supplement vendors, pushes developers toward advanced delivery technologies, and signals investors to scrutinize oral peptide claims.